We are a science-led global healthcare company on a mission: we want to help people do more, feel better, live longer. Today there are still millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments. At GSK we want to change this. We have three world-leading businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We are committed to widening access to our products, so more people can benefit, no matter where they live in the world or what they can afford to pay.

As a global healthcare company, we take on some of the world’s biggest healthcare challenges. By delivering a sustainable business, we provide health benefits to patients and consumers, improved shareholder returns as well as supporting wider society. Each of our three businesses benefits from GSK’s commercial infrastructure, integrated supply networks and significant global presence. At GSK, we believe how we do business is as important as what we do – it’s what makes us different - so we are challenging industry norms by changing the way we work.

Company Growth (employees)
Brentford, GB
Size (employees)
101,192 (est)
GlaxoSmithKline was founded in 2001 and is headquartered in Brentford, GB

Key People at GlaxoSmithKline

Andrew Philip Witty

Andrew Philip Witty

Emma Walmsley

Emma Walmsley

CEO of GSK Consumer Healthcare
Simon Dingemans

Simon Dingemans

David Redfern

David Redfern

Dan Troy

Dan Troy

General Counsel
Philip Thomson

Philip Thomson

SVP Global Communications & Government Affairs

GlaxoSmithKline Office Locations

GlaxoSmithKline has offices in Brentford, Tirana, Boudouaou Est, Buenos Aires and in 154 other locations
Brentford, GB
Baltimore, US
Dorset, GB
Izmir, TR
Phoenix, US
Santiago de Compostela, ES
Nairobi, KE
Petaling Jaya, MY
Prague, CZ
Budapest, HU
Ontario, US
Midland, US
Manchester, GB
Birmingham, US
Ottawa, CA
Irvine, US
Peoria, US
Guadalajara, MX
Zürich, CH

GlaxoSmithKline Metrics

GlaxoSmithKline Summary

Market capitalization

$103.1 b

Closing share price

GlaxoSmithKline's current market capitalization is $103.1 b.

GlaxoSmithKline Financials

GlaxoSmithKline's revenue is £23.9 b in FY, 2013 which is a 4% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


£23.9 b£23 b£23.9 b£27.9 b

Revenue growth, %


Cost of goods sold

£8.6 b£7.3 b£8.9 b£9.3 b

Cost of sales

£8.6 b£7.3 b£8.9 b

Gross profit

£15.3 b£15.7 b£15.1 b£18.6 b

Gross profit Margin, %


Sales and marketing expense

£8.5 b£8.2 b£9.2 b£9.4 b

R&D expense

£3.9 b£3.5 b£3.6 b£3.6 b

Operating expense total

£10.9 b£12.1 b£12.8 b£13 b

Interest expense

£767 m£727 m£757 m£736 m

Interest income

£104 m£68 m£104 m£72 m

Income tax expense

£1 b£137 m£2.2 b£877 m

Pre tax profit

£3 b£10.5 b£1.9 b

Net Income

£5.6 b£2.8 b£8.4 b£1.1 b

Operating cash flow

£2.6 b£5.2 b£7.2 b

GlaxoSmithKline Operating Metrics

GlaxoSmithKline had 2 b Volume of Medicines Produced in FY, 2016
Y, 2015FY, 2016

Drugs Approved by FDA


Ongoing Phase III Programs


Projects in R&D Pipeline


Volume of Medicines Produced

2 b

No. of Vaccines


Vaccines Delivered

833 m

Consumer Healthcare Products Produced

5 b

GlaxoSmithKline Market Value History

GlaxoSmithKline Revenue Breakdown

GlaxoSmithKline Online Presence

GlaxoSmithKline Company Life

You may also be interested in